Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Sep 9, 2020 | Press Releases

MARLBOROUGH, Mass., Sept. 9, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 12, 2020 | Press Releases

MARLBOROUGH, Mass., Aug. 12, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020

Jun 22, 2020 | Press Releases

Poster presented at the AACR Virtual Annual Meeting IIMARLBOROUGH, Mass., June 22, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering...

Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th

Jun 8, 2020 | Press Releases

MARLBOROUGH, Mass., June 8, 2020 /PRNewsire/ – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,...

Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity

May 29, 2020 | Press Releases

The new data was presented at the ASCO 2020 Virtual Scientific ProgramMARLBOROUGH, Mass., May 29, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary...